Raajit K. Rampal, MD, PhD, hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, discusses treatment for patients with AML that has evolved from myeloproliferative disorders (MPD). In general, patients with AML that has evolved from MPD have a genomic profile that portends the worst prognosis among all subtypes of AML. According to Dr Rampal, there is an unmet need in this population, highlighting the need to prioritize patients with post-MPD AML for clinical trials.